Procedures
death, Cancer
CANCER, DISEASE PROGRESSION, ADVERSE EVENT, ADVERSE EVENT
Patients received oral pyrotinib 400 mg once daily and oral capecitabine 1000 mg/mImaging examinations were performed every 6 weeks for the first 20 treatment cycles, and every 12 weeks thereafter. Radiological response was assessed by investigators according to RECIST 1.1. For patients who discontinued the study treatment before disease progression or death, subsequent imaging examinations were performed every 12 weeks until the initiation of other anti-cancer therapies, disease progression, or death. OS was followed every 12 weeks until loss to follow-up, death, or completion of the study. Adverse events (AEs) during the study treatment and until 28 days after the last dose of study drug were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03.